Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 3/20 | 0.47 |
| ▸ | FABP3 | P05413 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590319 | 0.87 | CA1 (0.53) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL10944689 | 0.85 | CA1 (0.51) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL4611906 | 0.85 | BCAT2 (0.41) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL363941 | 0.83 | IRAK4 (0.47) | CA1CA2TSHRCA12CA9 | |
| SCHEMBL8607514 | 0.83 | ALDH1A1 (0.42) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28987510 | 0.81 | CA1 (0.55) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL14443240 | 0.80 | CA1 (0.65) | CA1CA2TSHRCA9ALOX15 | |
| SCHEMBL16339817 | 0.80 | LMNA (0.47) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL34748 | 0.78 | BCAT2 (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29838630 | 0.78 | BCAT2 (0.62) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| EP-3458447-B1 | PIPERAZINYL METHANONE NAAA INHIBITORS | UNIV CALIFORNIA (US) | 2023-11-29 | — | — | EP | disclosed |
| US-10556892-B2 | Piperazinyl methanone NAAA inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| US-20190177313-A1 | PIPERZINYL METHANONE NAAA INHIBITORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-06-13 | — | — | US | disclosed |
| EP-3458447-A1 | PIPERAZINYL METHANONE NAAA INHIBITORS | The Regents of The University of California (US) | 2019-03-27 | — | — | EP | disclosed |
| CN-109476616-A | Piperazinyl methanone NAAA inhibitor | 加利福尼亚大学董事会 | 2019-03-15 | — | — | CN | disclosed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| WO-2017201103-A1 | PIPERAZINYL METHANONE NAAA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-23 | — | — | WO | disclosed |
| CN-104837843-A | Imidazopyridazine derivatives as GABAA receptor modulators | PFIZER | 2015-08-12 | — | — | CN | disclosed |
| EP-2396295-A1 | PHENOXY ACETIC ACID DERIVATIVES | Merck Serono S.A. (CH) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177313-A1 | PIPERZINYL METHANONE NAAA INHIBITORS | NAAA, NAA15, NAA50 | CA1 1762/4885CA2 2876/4885MMP1 1234/4885 |
| US-10556892-B2 | Piperazinyl methanone NAAA inhibitors | NAAA, NAA50, NAA15 | CA1 1783/4885CA2 2959/4885MMP1 1107/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CA1 3353/4885CA2 3978/4885MMP1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.